The DOI matches its Crossref record.
Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients
Open accessAbstract
There are few pathologic studies of gliomas in patients with neurofibromatosis type 1. We analyzed clinical and pathologic features of gliomas from 100 neurofibromatosis type 1 patients (57 men; 43 women). The median age at tumor diagnosis was 13 years (range, 4 months to 68 years). Most tumors were typical pilocytic astrocytoma (PA) (49%) or diffusely infiltrating astrocytoma (DA) (27%) that included World Health Organization Grades II (5%), III (15%), and IV (7%); others were designated as low-grade astrocytoma, subtype indeterminate (LGSI; 17%). Two pilomyxoid astrocytomas, 1 desmoplastic infantile ganglioglioma and 1 conventional ganglioglioma, were also identified. The tumors in 24 cases arose in the optic pathways and included PA (n = 14), LGSI (n = 4), DA (n = 4), pilomyxoid astrocytoma (n = 1), and ganglioglioma (n = 1). The prognoses of the PA and LGSI gliomas overall were generally favorable; there were no survival differences between PA and LGSI groups based on site, tumor size, mitotic activity, or MIB-1 labeling index. In the combined PA and LGSI group, age younger than 10 years and gross total resection were associated with an increased overall survival rate (p = 0.047 and 0.002, respectively). Compared with the combined group (PA + LGSI), patients with DA at all sites had decreased overall and recurrence-free survival times (p < 0.001 and p = 0.003, respectively). This study emphasizes the wide histologic spectrum of gliomas that occur in patients with neurofibromatosis type 1. Classic PA and LGSI are the most common, and most have favorable prognoses. By contrast, DAs are more aggressive, similar to those that arise sporadically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor
Ratner, N., & Miller, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3911 · Cited by 493
Pilocytic astrocytoma: pathology, molecular mechanisms and markers
Collins, V. P., Jones, D. T. W., & Giannini, C. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1410-7 · Cited by 445
Self-citationDistinctive Cancer Associations in Patients With Neurofibromatosis Type 1
Uusitalo, E., Rantanen, M., Kallionpää, R. A., Pöyhönen, M., Leppävirta, J., Ylä-Outinen, H., Riccardi, V. M., Pukkala, E., Pitkäniemi, J., Peltonen, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.3576 · Cited by 418
The landscape of the mesenchymal signature in brain tumours
Behnan, J., Finocchiaro, G., & Hanna, G. (2019) · Brain · doi:10.1093/brain/awz044 · Cited by 350
Long‐Term Epilepsy‐Associated Tumors
Thom, M., Blümcke, I., & Aronica, E. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00582.x · Cited by 231
Metadata
- Authors
- Rodriguez, F. J., Perry, A., Gutmann, D. H., O'Neill, B. P., Leonard, J., Bryant, S., & Giannini, C.
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03
- Volume
- 67
- Issue
- 3
- Pages
- 240-249
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W2038305873
- Cited by
- 190
- References
- 0
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients. https://app.cochat.ai/papers/10.1097/nen.0b013e318165eb75
- The paper
- Rodriguez, F. J., Perry, A., Gutmann, D. H., O'Neill, B. P., Leonard, J., Bryant, S., & Giannini, C. (2008). Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1097/nen.0b013e318165eb75
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.